Insiders · RLAY

Mark Murcko

Director at Relay Therapeutics, Inc. (RLAY)

Mark Murcko has filed 6 insider reports with the SEC since May 2022, as director at Relay Therapeutics, Inc. (RLAY). Mark Murcko made no open-market purchases or sales in the last 12 months. The latest filing, on June 10, 2026, reports grant or award at Relay Therapeutics, Inc. (RLAY).

Filings
6
Companies
1
Bought on market
None
Sold on market
$749K

Companies where Mark Murcko is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Relay Therapeutics, Inc. logo
RLAY
Relay Therapeutics, Inc.
Director996,952$749K$16.51Jun 10, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark Murcko with

Other insiders at the same companies

Questions about Mark Murcko

What is Mark Murcko's role at Relay Therapeutics, Inc.?
Mark Murcko reports to the SEC as director at Relay Therapeutics, Inc. (RLAY), according to the latest filing on June 10, 2026.
How many shares does Mark Murcko own?
After the latest filing that states it, Mark Murcko directly owned 996,952 shares of Relay Therapeutics, Inc. (RLAY). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Mark Murcko bought or sold stock recently?
The most recent open-market sale was on September 8, 2022: sold 25,000 shares of Relay Therapeutics, Inc. (RLAY) for $749K at an average of $29.95.
How do I get alerts when Mark Murcko files?
Follow Mark Murcko on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark Murcko (SEC CIK 0001816130). Totals count each trade once, skipping amendments whose original is on file, from May 27, 2022 on. View on SEC EDGAR